Aegis Capital Starts Rosetta Genomics (ROSG) at Buy, PT of $3.50
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Rosetta Genomics (ROSG) Receives U.S. Patent Allowance Related to microRNAs as Liver Cancer Treatment
January 11, 2016 9:12 AM ESTRosetta Genomics Ltd. (NASDAQ: ROSG) announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to Targeting microRNAs for the Treatment of Liver Cancer. This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq: RGLS). The patent claims chemically-modified,... More
